Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Back

HFA Premium Access

Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Session: Tailoring heart failure therapies on patient profiles

Topic: Pharmacotherapy

Speaker: Doctor M. Davies (The Woodlands, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Michael Davies

Lexicon Pharmaceuticals, Inc., The Woodlands (United States of America)

0 follower

6 more presentations in this session

A novel ERBB4 agonist attenuates cardiac remodelling after myocardial infarction in a sex-specific manner

Speaker: Miss B. Goovaerts (Antwerp, BE)

Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial.

Speaker: Professor J. Cleland (Glasgow, GB)

Sex differences in the prognostic role of achieving target doses of heart failure with reduced ejection fraction medications: data from the Swedish Heart Failure Registry

Speaker: Doctor D. Stolfo (Trieste, IT)

Phenotyping of patients with chronic obstructive pulmonary disease and heart failure: data from the swedish heart failure registry

Speaker: Assistant Professor P. Becher (Hamburg, DE)

Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

Speaker: Doctor D. Garcia Vega (Santiago de Compostela, ES)

Access the full session

Tailoring heart failure therapies on patient profiles

Speakers: Doctor M. Davies, Miss B. Goovaerts, Professor J. Cleland, Doctor D. Stolfo, Assistant Professor P. Becher...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources